I think there's a potential policy play in this. There is already a class of drugs, known as orphan drugs, which are targeted to rarer diseases that currently h

I think there's a potential policy play in this. There is already a class of drugs, known as orphan drugs, which are targeted to rarer diseases that currently have no gold standard treatment. Companies are incentivized by the US FDA to make drugs for these conditions. Maybe the FDA could also make a policy space for "cure incentives" which would provide additional economic benefits to companies willing to make drugs or protocols which attempt to cure disease.